Anti-mCD3-MDNA132

N/A

Report date: 2025/02/14 11:13:14
First In Class

Base Information

Drug NameAnti-mCD3-MDNA132
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-CD3Anti-IL13RA2
TargetsT cell surface glycoprotein CD3Interleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedicenna Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesMedicenna Therapeutics Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A